TT-10 is under clinical development by Portage Biotech and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TT-10’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TT-10 overview

PORT-6 is under development for the treatment of colon, metastatic renal cell carcinoma (RCC), metastatic castrate resistant prostate cancer (CRPC), solid tumors, colorectal cancer, endometrial cancer, ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), head and neck cancer and triple negative breast cancer. The drug candidate acts by targeting adenosine receptor (A2AR). It is administered through oral route.

Portage Biotech overview

Portage Biotech (Portage), formerly Bontan Corporation Inc, is a clinical- stage immune-oncology company. The company’s portfolio includes PORT-2 and PORT-3-iNKT agonists for the treatment of melanoma, solid tumors, NY-ESO-1 positive tumors, and NY-ESO-1 bladder and ovarian cancers; PORT-1 intratumoral amphiphilic formulations against early-stage breast and pancreatic cancer, sarcoma, cholangiocarcinoma, squamous cell, PORT-4-Nanolipogel formulations targeting solid tumors; and PORT-5-STING agonist with VLP delivery for solid tumors. Portage utilizes the invariant natural killer T-cells (iNKT cells) platform to develop treatments for cancer. The company is also investigating PORT-6 and PORT-7, adenosine inhibitors to treat A2A and A2B solid tumors. Portage Biotech is headquartered in Toronto, Ontario, Canada.

For a complete picture of TT-10’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.